PDT Partners’s Royalty Pharma RPRX Stock Holding History

PDT Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97M	Buy	+35,176	New	+$1.83M	0.1%	242
2025 Q4	–	Sell	-27,840	Closed	-$982K	–	639
2025 Q3	$982K	Sell	27,840 -41,693	-60%	-$1.51M	0.06%	361
2025 Q2	$2.51M	Sell	69,533 -100	-0.1%	-$3.31K	0.14%	256
2025 Q1	$2.17M	Buy	69,633 +100	+0.1%	+$3.17K	0.15%	233
2024 Q4	$1.77M	Buy	69,533 +38,599	+125%	+$1.02M	0.16%	233
2024 Q3	$875K	Sell	30,934 -20,502	-40%	-$568K	0.08%	396
2024 Q2	$1.36M	Buy	+51,436	New	+$1.43M	0.13%	281
2024 Q1	–	Sell	-121,059	Closed	-$3.4M	–	680
2023 Q4	$3.4M	Buy	121,059 +12,600	+12%	+$346K	0.38%	58
2023 Q3	$2.94M	Buy	108,459 +74,037	+215%	+$2.2M	0.37%	71
2023 Q2	$1.06M	Sell	34,422 -7,978	-19%	-$270K	0.15%	240
2023 Q1	$1.53M	Buy	+42,400	New	+$1.57M	0.21%	176

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's RPRX Position: Q2 2026 in Review

PDT Partners opened a new position in Royalty Pharma (RPRX) in Q2 2026: 35,176 shares worth $1.97M. The stake represents 0.1% of the portfolio and ranks #242 among its holdings. This is a return to the name: PDT Partners previously reported a position in RPRX as recently as Q3 2025.

PDT Partners first reported a position in RPRX in Q1 2023 and has held it in 11 quarters since. The position peaked at $3.4M in Q4 2023. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

PDT Partners held 35,176 shares of Royalty Pharma worth $1.97M as of Q2 2026.
Royalty Pharma was a new PDT Partners position in Q2 2026.
Royalty Pharma made up 0.1% of PDT Partners's portfolio in Q2 2026, its #242 holding.
PDT Partners first reported a position in Royalty Pharma in Q1 2023 and has held it in 11 quarters since.
PDT Partners's Royalty Pharma position peaked at $3.4M in Q4 2023.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.